Antidepressant use during pregnancy and the risk of autism spectrum disorder in children

JAMA Pediatrics

Volumn 170, Issue 2, 2016, Pages 117-124

  Boukhris, Takoua ^a,b   Sheehy, Odile ^b   Mottron, Laurent ^a,c   Berard, Anick ^a,b  

^a UNIVERSITÉ DE MONTRÉAL   (Canada)

^b UNIVERSITY OF MONTREAL   (Canada)

^c Hopital Riviere des Prairies   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDEPRESSANT AGENT; MONOAMINE OXIDASE INHIBITOR; SEROTONIN NORADRENALIN REUPTAKE INHIBITOR; SEROTONIN UPTAKE INHIBITOR;

ADULT; ARTICLE; AUTISM; CHILD; CLINICAL ASSESSMENT; CONTROLLED STUDY; DEPRESSION; DISEASE ASSOCIATION; DRUG USE; ENVIRONMENTAL EXPOSURE; FEMALE; FIRST TRIMESTER PREGNANCY; FOLLOW UP; GENETIC PREDISPOSITION; HUMAN; INFANT; LIVE BIRTH; MAJOR CLINICAL STUDY; MALE; MEDICAL HISTORY; OUTCOME ASSESSMENT; PREGNANCY; PRIORITY JOURNAL; PUERPERAL DEPRESSION; RISK ASSESSMENT; RISK FACTOR; SECOND TRIMESTER PREGNANCY; AUTISM SPECTRUM DISORDER; CHEMICALLY INDUCED; FETOMATERNAL TRANSFUSION; PREGNANCY COMPLICATION; PRENATAL EXPOSURE; PRESCHOOL CHILD; PROPORTIONAL HAZARDS MODEL; QUEBEC; THIRD TRIMESTER PREGNANCY;

ANTIDEPRESSIVE AGENTS; AUTISM SPECTRUM DISORDER; CHILD; CHILD, PRESCHOOL; DEPRESSION; FEMALE; HUMANS; INFANT; MALE; MATERNAL-FETAL EXCHANGE; PREGNANCY; PREGNANCY COMPLICATIONS; PREGNANCY TRIMESTER, SECOND; PREGNANCY TRIMESTER, THIRD; PRENATAL EXPOSURE DELAYED EFFECTS; PROPORTIONAL HAZARDS MODELS; QUEBEC; RISK FACTORS; SEROTONIN UPTAKE INHIBITORS;

EID: 84956894014     PISSN: 21686203     EISSN: None     Source Type: Journal    
DOI: 10.1001/jamapediatrics.2015.3356     Document Type: Article

References (41)

1. CooperWO, Willy ME, Pont SJ, RayWA. Increasing use of antidepressants in pregnancy. Am J Obstet Gynecol. 2007;196(6):544.e1-544.e5.
2. Daw JR, Mintzes B, LawMR, Hanley GE, Morgan SG. Prescription drug use in pregnancy: A retrospective, population-based study in British Columbia, Canada (2001-2006). Clin Ther. 2012;34 (1):239-249.e2.
3. KjaersgaardMI, Parner ET, VestergaardM, et al. Prenatal antidepressant exposure and risk of spontaneous abortion-A population-based study. PLoS One. 2013;8(8):e72095. doi:10.1371/journal .pone.0072095.
4. Gentile S. Selective serotonin reuptake inhibitor exposure during early pregnancy and the risk of birth defects. Acta Psychiatr Scand. 2011;123(4): 266-275.
5. Ross LE, Grigoriadis S, Mamisashvili L, et al. Selected pregnancy and delivery outcomes after exposure to antidepressant medication: A systematic review and meta-Analysis. JAMA Psychiatry. 2013;70(4):436-443.
6. Kl B. Neonate characteristics after maternal use of antidepressants in late pregnancy. Arch Pediatr Adolesc Med. 2004;158(4):312-316.
7. Nordeng H, Lindemann R, Perminov KV, ReikvamA. Neonatal withdrawal syndrome after in utero exposure to selective serotonin reuptake inhibitors. Acta Paediatr. 2001;90(3):288-291.
8. De VeraMA, Bard A. Antidepressant use during pregnancy and the risk of pregnancyinduced hypertension. Br J Clin Pharmacol. 2012;74 (2):362-369.
9. Yonkers KA, Gotman N, Smith MV, et al. Does antidepressant use attenuate the risk of a major depressive episode in pregnancy? Epidemiology. 2011;22(6):848-854.
10. Berard A, Karam F, Sheehy O, et al. Antidepressant use during pregnancy and the risk of delay in overall cognitive development at one year old: results from the OTIS Antidepressants Study. Birth Defects Res A Clin Mol Teratol. 2012;94: 364-374. doi:10.1002/bdra.23023.
11. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 4th ed, text revision.Washington, DC: American Psychiatric Association; 2000.
12. Centers for Disease Control and Prevention. Prevalence of autism spectrum disorders-Autism and Developmental Disabilities Monitoring Network, 14 Sites, United States, 2008. MMWR Surveill Summ. 2012;61(3):1-19.
13. Fombonne E. Is there an epidemic of autism? Pediatrics. 2001;107(2):411-412.
14. Lee BK, McGrath JJ. Advancing parental age and autism:multifactorial pathways. Trends MolMed. 2015;21(2):118-125.
15. Christensen J, Grborg TK, Sensen MJ, et al. Prenatal valproate exposure and risk of autism spectrum disorders and childhood autism. JAMA. 2013;309(16):1696-1703.
16. Hertz-Picciotto I, Croen LA, Hansen R, Jones CR, van deWater J, Pessah IN. The CHARGE study: An epidemiologic investigation of genetic and environmental factors contributing to autism. Environ Health Perspect. 2006;114(7):1119-1125.
17. De Rubeis S, Buxbaum JD. Recent advances in the genetics of autism spectrum disorder. Curr Neurol Neurosci Rep. 2015;15(6):36.
18. Ronemus M, Iossifov I, Levy D, WiglerM. The role of de novo mutations in the genetics of autism spectrum disorders. Nat Rev Genet. 2014;15 (2):133-141.
19. Lyall K, Pauls DL, Spiegelman D, Ascherio A, Santangelo SL. Pregnancy complications and obstetric suboptimality in association with autism spectrum disorders in children of the Nurses Health Study II. Autism Res. 2012;5(1):21-30.
20. Jokiranta E, Brown AS, Heinimaa M, Cheslack-Postava K, Suominen A, Sourander A. Parental psychiatric disorders and autism spectrum disorders. Psychiatry Res. 2013;207(3):203-211.
21. Sensen MJ, Grborg TK, Christensen J, et al. Antidepressant exposure in pregnancy and risk of autism spectrum disorders. Clin Epidemiol. 2013;5: 449-459.
22. Rai D, Lee BK, Dalman C, Golding J, Lewis G, Magnusson C. Parental depression, maternal antidepressant use during pregnancy, and risk of autism spectrum disorders: population based case-control study. BMJ. 2013;346:f2059.
23. Hviid A, Melbye M, Pasternak B. Use of selective serotonin reuptake inhibitors during pregnancy and risk of autism. N Engl J Med. 2013; 369(25):2406-2415.
24. Gidaya NB, Lee BK, Burstyn I, YudellM, Mortensen EL, Newschaffer CJ. In utero exposure to selective serotonin reuptake inhibitors and risk for autism spectrum disorder. J Autism Dev Disord. 2014;44(10):2558-2567.
25. Murray CL, Lopez AD. The Global Burden of Disease: A Comprehensive Assessment of Mortality and Disability From Diseases, Injuries, and Risk Factors in 1990 and Projected to 2020. Boston, MA: Harvard School of Public Health; 1996.
26. Vilain A, Otis S, Forget A, Blais L. Agreement between administrative databases and medical charts for pregnancy-related variables among asthmatic women. Pharmacoepidemiol Drug Saf. 2008;17(4):345-353.
27. Bard A, Sheehy O. The Quec Pregnancy Cohort-prevalence of medication use during gestation and pregnancy outcomes. PLoS One. 2014;9(4):e93870. doi:10.1371/journal.pone.
28. Jobin-Gervais K, Sheehy O, Bard A. Can we rely on pharmacy claims databases to ascertain maternal use of medications during pregnancy? Pharmacoepidemiol Drug Saf. 2013;22:155. doi:10.1002/pds.3512.
29. Huang H, Coleman S, Bridge JA, Yonkers K, KatonW. Ameta-Analysis of the relationship between antidepressant use in pregnancy and the risk of preterm birth and low birth weight. Gen Hosp Psychiatry. 2014;36(1):13-18.
30. Boukhris T, Bard A. Selective serotonin reuptake inhibitor use during pregnancy and the risk of autism spectrum disorders: A review. J Pediatr Genet. 2015;4(2):84-93.
31. Chakrabarti S, Fombonne E. Pervasive developmental disorders in preschool children. JAMA. 2001;285(24):3093-3099.
32. Fombonne E. Epidemiology of pervasive developmental disorders. Pediatr Res. 2009;65(6): 591-598.
33. Rampono J, Simmer K, Ilett KF, et al. Placental transfer of SSRI and SNRI antidepressants and effects on the neonate. Pharmacopsychiatry. 2009; 42(3):95-100.
34. Loughhead AM, Fisher AD, Newport DJ, et al. Antidepressants in amniotic fluid: Another route of fetal exposure. Am J Psychiatry. 2006;163(1):145-147.
35. Gaspar P, Cases O, Maroteaux L. The developmental role of serotonin: news from mouse molecular genetics. Nat Rev Neurosci. 2003;4(12): 1002-1012.
36. Tordjman S, Anderson GM, Cohen D, et al. Presence of autism, hyperserotonemia, and severe expressive language impairment in Williams-Beuren syndrome. Mol Autism. 2013;4(1):29.
37. Chandana SR, Behen ME, Juhz C, et al. Significance of abnormalities in developmental trajectory and asymmetry of cortical serotonin synthesis in autism. Int J Dev Neurosci. 2005;23 (2-3):171-182.
38. Murphy DG, Daly E, Schmitz N, et al. Cortical serotonin 5-HT2A receptor binding and social communication in adults with Aspergers syndrome: An in vivo SPECT study. Am J Psychiatry. 2006;163(5):934-936.
39. Avorn J, Monette J, Lacour A, et al. Persistence of use of lipid-lowering medications: A cross-national study. JAMA. 1998;279(18): 1458-1462.
40. De Jong van den Berg LT, Feenstra N, Sorensen HT, Cornel MC; Europen Medicine and Pregnancy Group. Improvement of drug exposure data in a registration of congenital anomalies: pilot-study: pharmacist and mother as sources for drug exposure data during pregnancy: EuroMAP Group. Teratology. 1999;60(1):33-36.
41. Bard A, Lacasse A. Validity of perinatal pharmacoepidemiologic studies using data from the RAMQ administrative database. Can J Clin Pharmacol. 2009;16(2):e360-e369.